Clinical Trials Logo

Treatment Related Cancer clinical trials

View clinical trials related to Treatment Related Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04034173 Not yet recruiting - Clinical trials for Treatment Related Cancer

Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation

Start date: August 1, 2019
Phase: Phase 2
Study type: Interventional

The present hypothesis is that anti-EGFR agents are active in tumors with low-level RAS mutation when the majority of tumor cells is still sensitive. While response rate may be high and may reflect sensitivity to anti-EGFR agents, PFS is anticipated to be shorter than in RAS wild-type patients due to the faster development of resistance when sensitive cells are eradicated and when the RAS-mutant anti-EGFR resistant clones become predominant. The characteristics of low-level RAS mutant tumors would be: - Objective response rate (ORR) high (reflecting the sensitive clone) - Progression-free survival (PFS) short (reflecting the more rapid outgrowth of RAS mutant clones)